Form 4: Upstream Bio, Inc. Chief Medical Officer Acquires Stock Options
SEC Form 4 Filing
Aaron Deykin, Chief Medical Officer of Upstream Bio, Inc., was granted stock options for 165,000 shares of common stock on February 6, 2025, according to a Form 4 filing.
Summary
- A Form 4 filing reveals that Aaron Deykin, the Chief Medical Officer of Upstream Bio, Inc., acquired stock options.
- The transaction occurred on February 6, 2025.
- Deykin received options for 165,000 shares of Upstream Bio's common stock at an exercise price of $8.53 per share.
- The options vest in 48 equal monthly installments starting February 6, 2025, contingent upon continued service.
- Allison Ambrose, as Attorney-in-Fact, signed the filing on February 7, 2025, using a substitute power of attorney.
- Michael Gray appointed Allison Ambrose as substitute attorney-in-fact on December 19, 2024, for individuals including Aaron Deykin.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and generally viewed as a positive sign of aligning management interests with shareholders.
Positives
- The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies, similar to companies like Amgen, Regeneron, and Gilead.
- The vesting schedule of 48 months is also typical in the industry, aligning with standard retention practices.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2024-10-10 | Date of original powers of attorney. |
| 2024-12-19 | Michael Gray appointed Allison Ambrose as substitute attorney-in-fact. |
| 2025-02-06 | Date of stock option grant to Aaron Deykin. |
| 2025-02-06 | First vesting date of the stock options. |
| 2025-02-07 | Date of Form 4 filing. |
| 2035-02-05 | Expiration date of the stock options. |
Keywords
Form 4, Stock Options, Upstream Bio, Aaron Deykin, Chief Medical Officer, Beneficial Ownership, Securities, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.